|2.||Neoplasm Metastasis (Metastasis)
|1.||Saif, Muhammad Wasif: 127 articles (12/2015 - 07/2005)|
|2.||Friess, Helmut: 119 articles (07/2015 - 01/2002)|
|3.||Büchler, Markus W: 113 articles (06/2015 - 01/2002)|
|4.||Abbruzzese, James L: 106 articles (09/2015 - 01/2002)|
|5.||Maitra, Anirban: 105 articles (10/2015 - 04/2002)|
|6.||Hruban, Ralph H: 84 articles (01/2016 - 03/2002)|
|7.||Tanaka, Masao: 84 articles (10/2015 - 01/2002)|
|8.||Sarkar, Fazlul H: 73 articles (12/2015 - 01/2002)|
|9.||Kleeff, Jörg: 72 articles (07/2015 - 01/2002)|
|10.||Mizumoto, Kazuhiro: 65 articles (10/2015 - 01/2002)|
01/01/2009 - "Single-agent gemcitabine has been established as standard treatment for advanced pancreatic cancer since clinical studies have shown an improvement in overall survival and significant clinical benefit when compared to the best supportive care despite low overall objective response. "
09/01/2012 - "Gemcitabine is currently the best treatment available for pancreatic cancer (PaCa); however, patients with the disease develop resistance to the drug over time. "
05/01/2011 - "Gemcitabine is currently the best treatment available for pancreatic cancer, but causes high toxicity. "
12/01/2010 - "Most pancreatic cancer patients are diagnosed at the advanced stages, and no therapy is superior to gemcitabine alone. "
04/15/2007 - "Gemcitabine is currently the best treatment available for pancreatic cancer, but the disease develops resistance to the drug over time. "
|2.||Fluorouracil (Carac)FDA LinkGeneric
01/01/1998 - "Although concomitant radiation therapy (RT) and bolus 5-Fluorouracil (5-FU) have been shown to improve survival in locally confined pancreatic cancer, most patients will eventually succumb to their disease. "
04/01/1992 - "Our preliminary data suggest that biochemical modulation of 5-FU with FA and IFN-alpha (reduced dosage) is effective in pancreatic cancer with moderate toxicity, warranting further study."
07/01/2006 - "IFN-Alpha + CDDP + 5-FU therapy is an effective treatment for GEM-refractory pancreatic cancer, but with moderate toxicity."
01/01/2011 - "In this study, we investigated the associations between polymorphisms of the TS gene and its protein expression, and the implications on the efficacy of 5-fluorouracil (5-FU) in pancreatic cancer cells. "
02/01/2010 - "The efficacy of 5-FU may be lower in pancreatic cancer tissue than in normal tissue because DPD activity is upregulated in pancreatic cancer tissue compared to normal pancreatic tissue. "
|3.||erlotinib (CP 358,774)FDA Link
11/01/2013 - "We evaluated the efficacy of erlotinib plus GEM in patients with unresectable pancreatic cancer. "
04/01/2013 - "It has not yet been defined if KRAS has a prognostic value or is a predictive biomarker for the efficacy of erlotinib in advanced pancreatic cancer (PC). "
01/01/2014 - "Within the phase III study AIO-PK0104 281 patients with advanced pancreatic cancer received an erlotinib-based 1st-line regimen. "
07/01/2008 - "Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?"
06/01/2008 - "Only studies using erlotinib in pancreatic cancer patients were reviewed and analyzed. "
|4.||oxaliplatin (Eloxatin)FDA LinkGeneric
07/01/2004 - "It is hypothesized that well designed, personalized, molecular-based treatments may improve the efficacy of oxaliplatin for the treatment of colorectal, gastric and pancreatic cancer. "
05/20/2005 - "Given the promising phase II results obtained with the Gem-oxaliplatin (GemOx) combination, we conducted a phase III study comparing GemOx with Gem alone in advanced pancreatic cancer. "
01/01/2005 - "A phase II study was designed to evaluate the efficacy and safety of oxaliplatin as second-line treatment in patients with locally advanced or metastatic pancreatic cancer. "
01/01/2005 - "Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study."
11/01/2003 - "On the basis of these encouraging results, phase III studies of oxaliplatin in advanced pancreatic cancer are now in progress in Europe and the United States. "
|5.||Cisplatin (Platino)FDA LinkGeneric
01/01/2012 - "Indeed, they exhibit much higher in vitro cytotoxicity than cisplatin, and we have recently found one of the dinuclear Pt(II) complexes exhibits markedly high in vivo antitumor efficacy against pancreatic cancer. "
07/01/2008 - "S-1 with low-dose cisplatin is well tolerated and effective for advanced pancreatic cancer."
11/01/2002 - "The aim of this study was to evaluate the feasibility and efficacy of S-1 administered as a single-agent and in combination with cisplatin, for the treatment of patients with pancreatic cancer. "
07/01/2008 - "A phase 2 trial of S-1 combined with cisplatin was conducted for unresectable pancreatic cancer. "
07/01/2008 - "Phase 2 trial of oral S-1 combined with low-dose cisplatin for unresectable advanced pancreatic cancer."
|6.||Leucovorin (Folinic Acid)FDA Link
09/01/1998 - "However, there are no published data regarding the efficacy of leucovorin-modulated UFT in patients with pancreatic cancer. "
09/01/1997 - "Our current trial is designed primarily to assess the efficacy in terms of response rates to UFT with leucovorin in patients with advanced hepatobiliary and pancreatic cancer. "
12/01/2005 - "Between 1994 and 2003, 68 patients with non-resectable pancreas cancer TNM stage III and IV, were enrolled to receive intraperitoneal5-FU instillation 750-1500 mg/m2 and intravenous Leucovorin 100 mg/m2 for two days every third week. "
07/01/2000 - "Oral UFT/leucovorin and radiation therapy offers patients a viable treatment option for pancreatic cancer. "
07/01/1999 - "UFT/oral calcium folinate plus radiation in pancreatic cancer."
|7.||Biological Markers (Surrogate Marker)IBA
01/01/2015 - "This study opens up an interesting avenue of investigation to potentially identify predictive biomarkers and novel therapeutic targets for pancreatic cancer, a disease that has seen no significant improvement in survival over the past 40 years."
01/01/2012 - "In order to achieve a better outcome for pancreatic cancer patients, reliable biomarkers are required which allow for improved diagnosis. "
03/01/2004 - "If pancreatic cancer could be diagnosed more readily and accurately using serum markers, patient survival could theoretically be improved by enabling more patients to avail of surgical resection. "
02/01/1999 - "However, the improvement in diagnostic accuracy is still not satisfactory in spite of an elaborate combination of serum markers in diagnosis for pancreatic cancer. "
06/01/2015 - "These biomarkers provide useful insight into potentially discovering new markers for early detection or elucidating the efficacy of treatment on pancreatic cancers. "
|8.||capecitabine (Xeloda)FDA Link
09/01/2014 - "We report a case of an interesting observation in a patient with pancreatic cancer receiving capecitabine whose HFS was improved with the use of "henna". "
01/01/2013 - "Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer."
01/01/2010 - "We evaluated safety and efficacy of concurrent chemoradiotherapy (CCRT) with capecitabine in patients with locally advanced pancreatic cancer (LAPC). "
01/01/2002 - "To determine the safety and efficacy of capecitabine (Xeloda; Roche Laboratories, Nutley, NJ) in patients with metastatic or unresectable, locally advanced pancreatic cancer. "
01/01/2014 - "Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer."
|9.||irinotecan (Camptosar)FDA LinkGeneric
03/01/2007 - "Single-agent irinotecan has significant efficacy for metastatic pancreatic cancer. "
05/07/2007 - "To confirm the efficacy of PMX-CPT-11 combination, we extended the study to a panel of 10 pancreatic cancer cell lines using clinically relevant concentrations (PMX 10 microM; CPT-11 1 microm). "
01/01/2013 - "The aim of this study was to evaluate the efficacy and safety of irinotecan monotherapy in patients with advanced pancreatic cancer (APC). "
06/01/2010 - "Phase I study of daily irinotecan as a radiation sensitizer for locally advanced pancreatic cancer."
01/01/2008 - "The aim of this study was to evaluate the efficacy and safety of a combination regimen using irinotecan plus S-1 in patients with metastatic pancreatic cancer. "
|10.||Epidermal Growth Factor Receptor (EGF Receptor)IBA
02/15/2009 - "Novel therapeutic agents targeting the epidermal growth factor receptor (EGFR) have improved outcomes for a subgroup of patients with colorectal, lung, head and neck, and pancreatic cancers. "
09/01/2008 - "The epidermal growth factor receptor ErbB-1 is commonly expressed in pancreatic cancer and ErbB-1 targeting has shown promising results. "
03/01/2007 - "In addition, the data support the efficacy of combined epidermal growth factor receptor and MAPK inhibitors in biliary and pancreatic cancers, providing the basis to test this combination in the clinic."
06/01/2012 - "In this article, we review the epidermal growth factor receptor signaling network in pancreatic cancer, the strategies to increase the effectiveness of epidermal growth factor receptor inhibitors, and the clinical trials of these inhibitors in pancreatic cancer."
05/01/2011 - "In this study, we sought to identify gene targets that, when inhibited, would enhance the activity of epidermal growth factor receptor (EGFR)-targeted therapies in pancreatic cancer cells. "
|1.||Drug Therapy (Chemotherapy)
01/01/2011 - "The impact of adjuvant treatment, especially chemotherapy, has increased dramatically within recent years, leading to significantly improved postoperative survival, making pancreatic cancer therapy an interdisciplinary approach to achieve best results. "
01/01/2008 - "Which is the best monitoring modality to evaluate the efficacy of chemotherapy on unresectable pancreatic cancer ? "
01/01/2006 - "Chemotherapy remains the mainstay of treatment for pancreatic cancer as most patients present with advanced disease, which precludes locoregional treatment. "
11/01/2014 - "Neoadjuvant chemotherapy is important for effective treatment of locally advanced pancreatic cancer."
02/01/2014 - "The Akt signaling pathway mediates a potent anti-apoptotic signal in pancreatic cancer and inhibition of this pathway has become an attractive mechanism to increase the efficacy of traditional chemotherapies. "
|2.||Heterologous Transplantation (Xenotransplantation)
09/01/2008 - "The aim of this study was to investigate AdbCD-D314A/5-FC-mediated cytotoxicity in vitro and therapeutic efficacy in vivo alone and in combination with radiation against human pancreatic cancer cells and xenografts. "
09/01/2013 - "A xenograft model in nude mice was used to determine pancreatic cancer tumorigenesis and therapeutic efficacy of TRA-8, a monoclonal agonistic antibody for DR5. "
01/01/2008 - "Improved therapeutic efficacy is shown with pretargeting in a pancreatic cancer xenograft model given a tri-Fab to a pancreatic cancer MUC1 and the hapten peptide labeled with (90)Y."
05/15/2006 - "Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus."
05/16/1997 - "We examined the therapeutic efficacy of 131I-labeled murine monoclonal antibody (MAb) PAM4 against human pancreatic cancers carried as xenografts in athymic nude mice. "
11/01/2008 - "3-D conformal gamma-knife radiotherapy combined with thermochemotherapy is well tolerated and is relatively effective for most patients with locally advanced pancreatic cancer."
10/01/2011 - "Thus, strategies to improve the efficacy of radiotherapy in pancreatic cancer are important to pursue. "
04/01/2002 - "Because radiation may increase invasion ability through activating MMP proteolytic system, simultaneous administration of the MMP inhibitor during radiotherapy could be a potent adjuvant therapeutic approach to improve the efficacy of radiotherapy for pancreatic cancer."
05/01/2014 - "Radiotherapy for isolated locally recurrent pancreatic cancer resulted in encouraging local control, overall survival, and palliative effects with mild toxicity, particularly in patients with a prolonged disease-free interval. "
02/01/2009 - "S-1 and concurrent radiotherapy shows favorable efficacy for disease control against locally advanced pancreatic cancer and was well tolerated with no severe toxicities."
01/01/2005 - "Cephalic pancreaticoduodenectomy is the best treatment for cephalic pancreas cancers. "
08/01/2014 - "Pancreatoduodenectomy with portal vein resection is safe and potentially beneficial for elderly patients with pancreatic cancer."
08/01/2014 - "Pancreatoduodenectomy with portal vein resection is feasible and potentially beneficial for elderly patients with pancreatic cancer."
12/01/2008 - "Although the safety of pancreaticoduodenectomy has notably improved over the past several decades, the reported survival of patients with pancreatic cancer remains poor. "
05/01/1989 - "It is debatable that any case demonstrating intramural spread within the duodenum could be cured with a standard Whipple resection as this may well represent another sign of incurability, like lymphatic or perineural spread, but it is clearly a major potential obstacle to palliation if submucosal recurrences occur as a result of the use of the pylorus-sparing pancreatoduodenectomy in cases of pancreatic cancer. "
11/01/2014 - "Our objective was to retrospectively evaluate whether postoperative adjuvant chemotherapy using S-1 is clinically beneficial in managing resectable pancreatic cancer. "
02/01/2003 - "In addition, 34.7% (25/72) of the cases harbor p53 polymorphism mutation only at codon-72 of exon-4, which did not show any significant effect on the pathology, prognosis, and efficacy of adjuvant chemotherapy of the pancreatic cancers. "
03/01/1999 - "Evaluation of expression of p53 and WAF/1-p21 may be beneficial in the prediction of the patient's prognosis as well as prediction of the effects of adjuvant chemotherapy in pancreatic cancer patients."
11/01/2011 - "After a lengthy search for an effective treatment for resected pancreatic cancer, evidence accumulated in the past 10 years shows that adjuvant chemotherapy is firmly established as offering a modest but real improvement in overall survival. "
11/10/2001 - "Interpretation This study showed no survival benefit for adjuvant chemoradiotherapy but revealed a potential benefit for adjuvant chemotherapy, justifying further randomised controlled trials of adjuvant chemotherapy in pancreatic cancer."